Diabetes in Children: Type 1 vs Type 2, Warning Signs

✓ Medically reviewed | Published: | Evidence level: 1A
Childhood diabetes is dominated by type 1, an autoimmune condition, but type 2 is increasingly diagnosed in young people. Newer tools, including continuous glucose monitors and the immune therapy teplizumab, are changing how families manage and even delay disease.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pediatric Health

Quick Facts

Children with type 1 diabetes
Over 1 million worldwide
Teplizumab approval
FDA, November 2022
Classic symptoms
Thirst, urination, weight loss

What are the types of diabetes in children and how do they differ?

Quick answer: Type 1 is an autoimmune loss of insulin production and is most common in children, while type 2 involves insulin resistance and is linked to excess weight.

In type 1 diabetes, the immune system destroys insulin-producing beta cells in the pancreas, so children need lifelong insulin. The International Diabetes Federation estimates that well over a million children and adolescents under 20 live with type 1 diabetes worldwide. It is not caused by diet or lifestyle, and onset is often sudden, with increased thirst, frequent urination, unexplained weight loss, fatigue and sometimes diabetic ketoacidosis, a medical emergency.

Type 2 diabetes, once rare in youth, is now seen more often, particularly in adolescents with obesity, a family history of diabetes, or certain ethnic backgrounds. It develops more gradually and may be found on screening. Rarer forms include monogenic diabetes, caused by single-gene variants, which can be misdiagnosed as type 1 or 2 and may respond to different treatment.

What treatment advances are helping children with diabetes?

Quick answer: Continuous glucose monitors, automated insulin delivery systems and the immune therapy teplizumab are among the major advances.

Continuous glucose monitoring and insulin pumps linked to algorithms, often called automated insulin delivery or hybrid closed-loop systems, have improved glucose control and reduced the burden of constant fingersticks for many families. The American Diabetes Association Standards of Care recommend considering these technologies for children with type 1 diabetes.

In November 2022 the FDA approved teplizumab, an anti-CD3 antibody, to delay the onset of stage 3 type 1 diabetes in people aged 8 and older with stage 2 disease. This is the first therapy approved to delay clinical onset, and it underscores the value of autoantibody screening in relatives of affected people. For youth-onset type 2 diabetes, treatment includes lifestyle change, metformin, insulin when needed, and selected additional agents approved for pediatric use. Families should seek care promptly if a child shows classic symptoms, especially vomiting, rapid breathing or drowsiness.

Frequently Asked Questions

No proven method prevents it. Teplizumab can delay onset in some people with stage 2 disease aged 8 and older, identified through autoantibody screening.

Increased thirst, frequent urination, unexplained weight loss, tiredness and blurred vision. Vomiting, abdominal pain or fast breathing can signal ketoacidosis and need emergency care.

References

  1. International Diabetes Federation. IDF Diabetes Atlas.
  2. American Diabetes Association. Standards of Care in Diabetes: Children and Adolescents.
  3. U.S. Food and Drug Administration. FDA approves first drug that can delay onset of type 1 diabetes. November 2022.